期刊
NATURE REVIEWS NEUROLOGY
卷 11, 期 10, 页码 553-554出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrneurol.2015.150
关键词
-
The results of a futility trial, which used the PPAR-gamma receptor agonist pioglitazone in an attempt to modify disease progression in Parkinson disease, do not support initiation of further trials. However, although this trial was well designed and conducted, we question whether it is time to fully shut the door on pioglitazone.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据